dc.creator | Delgado Valverde, María Mercedes | es |
dc.creator | Portillo Calderón, Inés María | es |
dc.creator | Alcalde Rico, Manuel | es |
dc.creator | Conejo Gonzalo, Mª Carmen | es |
dc.creator | Hidalgo, Carmen | es |
dc.creator | Del Toro Esperón, Carlos | es |
dc.creator | Pascual Hernández, Álvaro | es |
dc.date.accessioned | 2024-01-24T16:50:30Z | |
dc.date.available | 2024-01-24T16:50:30Z | |
dc.date.issued | 2023-12-29 | |
dc.identifier.citation | Delgado Valverde, M.M., Portillo Calderón, I.M., Alcalde Rico, M., Conejo Gonzalo, M.C., Hidalgo, C., Del Toro Esperón, C. y Pascual Hernández, Á. (2023). Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. European journal of clinical microbiology & infectious diseases. https://doi.org/10.1007/s10096-023-04735-1. | |
dc.identifier.issn | 0934-9723 | es |
dc.identifier.uri | https://hdl.handle.net/11441/153939 | |
dc.description.abstract | Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain.
Methods: Six hundred and seventy-eight isolates were tested: 265 K. pneumoniae (230 ST512/KPC-3 and 35 ST258/KPC-3) and 413 carbapenem-non-susceptible P. aeruginosa. Imipenem, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane/tazobactam, meropenem, amikacin, ciprofloxacin, colistin, and ceftazidime/avibactam were used as comparators against P. aeruginosa. Against K. pneumoniae ceftazidime, cefepime, aztreonam, and ceftolozane/tazobactam were not tested, and tigecycline was studied instead. MICs were determined in duplicate by broth microdilution according to EUCAST guidelines.
Results: Imipenem/relebactam displayed potent in vitro activity against both sequence types of KPC-3-producing K. pneumoniae. MIC50 and MIC90 values were 0.25 mg/L and 1 mg/L, respectively, with percent of susceptible isolates >97%. Only three K. pneumoniae ST512/KPC-3 isolates and one ST258/KPC-3 were resistant to imipenem/relebactam. Relebactam sensitized 98.5% of K. pneumoniae isolates resistant to imipenem. The activity of imipenem/relebactam against P. aeruginosa was moderate (susceptibility rate: 62.7%). Analysis of the acquired and mutational resistome of isolates with high levels of resistance to imipenem/relebactam has not shown a clear association between them.
Conclusion: Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | European journal of clinical microbiology & infectious diseases. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Imipenem/relebactam | es |
dc.subject | P. aeruginosa | es |
dc.subject | K. pneumoniae | es |
dc.subject | Carbapenem-resistant | es |
dc.title | Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s10096-023-04735-1 | es |
dc.identifier.doi | 10.1007/s10096-023-04735-1 | es |
dc.contributor.group | Universidad de Sevilla. CTS-210: Resistencia a antimicrobianos | es |
dc.journaltitle | European journal of clinical microbiology & infectious diseases | es |